These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

222 related articles for article (PubMed ID: 16453992)

  • 1. Screening and treatment of hypercholesterolemia for prevention of coronary heart disease.
    Wang YR; Alexander GC; Meltzer DO
    Manag Care Interface; 2006 Jan; 19(1):25-9. PubMed ID: 16453992
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Low-density lipoprotein cholesterol (LDL-C) levels and LDL-C goal attainment among elderly patients treated with rosuvastatin compared with other statins in routine clinical practice.
    Harley CR; Gandhi S; Blasetto J; Heien H; Sasane R; Nelson SP
    Am J Geriatr Pharmacother; 2007 Sep; 5(3):185-94. PubMed ID: 17996658
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Consistency of lipid-altering effects of ezetimibe/simvastatin across gender, race, age, baseline low density lipoprotein cholesterol levels, and coronary heart disease status: results of a pooled retrospective analysis.
    Ose L; Shah A; Davies MJ; Rotonda J; Maccubbin D; Tribble D; Veltri E; Mitchel Y
    Curr Med Res Opin; 2006 May; 22(5):823-35. PubMed ID: 16709304
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The patient at risk: who should we be treating?
    Leitersdorf E
    Br J Clin Pract Suppl; 1994 Dec; (77):24-7. PubMed ID: 19496269
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prevalence of low high-density lipoprotein cholesterol in patients with documented coronary heart disease or risk equivalent and controlled low-density lipoprotein cholesterol.
    Alsheikh-Ali AA; Lin JL; Abourjaily P; Ahearn D; Kuvin JT; Karas RH
    Am J Cardiol; 2007 Nov; 100(10):1499-501. PubMed ID: 17996508
    [TBL] [Abstract][Full Text] [Related]  

  • 6. National improvements in low-density lipoprotein cholesterol management of individuals at high coronary risk: National Health and Nutrition Examination Survey, 1999 to 2002.
    Cullen MW; Stein JH; Gangnon R; McBride PE; Keevil JG
    Am Heart J; 2008 Aug; 156(2):284-91. PubMed ID: 18657658
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Titration patterns with rosuvastatin as compared with other statins in clinical practice: a retrospective observational cohort study using an electronic medical record database.
    Fox KM; Gandhi SK; Ohsfeldt RL; Blasetto JW; Davidson MH
    Clin Ther; 2007 Nov; 29(11):2385-94. PubMed ID: 18158079
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effectiveness of the addition of ezetimibe to ongoing statin therapy in modifying lipid profiles and attaining low-density lipoprotein cholesterol goals in older and elderly patients: subanalyses of data from a randomized, double-blind, placebo-controlled trial.
    Pearson T; Denke M; McBride P; Battisti WP; Brady WE; Palmisano J
    Am J Geriatr Pharmacother; 2005 Dec; 3(4):218-28. PubMed ID: 16503317
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Gap between guidelines and practice: attainment of treatment targets in patients with primary hypercholesterolemia starting statin therapy. Results of the 4E-Registry (Efficacy Calculation and Measurement of Cardiovascular and Cerebrovascular Events Including Physicians' Experience and Evaluation).
    Assmann G; Benecke H; Neiss A; Cullen P; Schulte H; Bestehorn K
    Eur J Cardiovasc Prev Rehabil; 2006 Oct; 13(5):776-83. PubMed ID: 17001218
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of fluvastatin extended-release (80 mg) alone and in combination with ezetimibe (10 mg) on low-density lipoprotein cholesterol and inflammatory parameters in patients with primary hypercholesterolemia: a 12-week, multicenter, randomized, open-label, parallel-group study.
    Alvarez-Sala LA; Cachofeiro V; Masana L; Suarez C; Pinilla B; Plana N; Trias F; Moreno MA; Gambus G; Lahera V; Pintó X
    Clin Ther; 2008 Jan; 30(1):84-97. PubMed ID: 18343245
    [TBL] [Abstract][Full Text] [Related]  

  • 11. 5-year evaluation of electronic medical record flag alerts for patients warranting secondary prevention of coronary heart disease.
    Whitley HP; Fermo JD; Chumney EC
    Pharmacotherapy; 2006 May; 26(5):682-8. PubMed ID: 16637797
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment and secondary prevention of ischemic coronary events in Croatia (TASPIC-CRO study).
    Reiner Z; Mihatov S; Milicić D; Bergovec M; Planinc D;
    Eur J Cardiovasc Prev Rehabil; 2006 Aug; 13(4):646-54. PubMed ID: 16874158
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hypercholesterolemia. The NCEP Adult Treatment Panel III Guidelines.
    Morgan JM; Capuzzi DM
    Geriatrics; 2003 Aug; 58(8):33-8; quiz 41. PubMed ID: 12938250
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Relation of clinical benefit of raising high-density lipoprotein cholesterol to serum levels of low-density lipoprotein cholesterol in patients with coronary heart disease (from the Bezafibrate Infarction Prevention Trial).
    Goldenberg I; Benderly M; Sidi R; Boyko V; Tenenbaum A; Tanne D; Behar S
    Am J Cardiol; 2009 Jan; 103(1):41-5. PubMed ID: 19101227
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Intensity of lipid-lowering therapy and low-density lipoprotein cholesterol goal attainment among the elderly before and after the 2004 National Cholesterol Education Program Adult Treatment Panel III update.
    Nichols GA; Nag S; Chan W
    Am Heart J; 2007 Sep; 154(3):554-60. PubMed ID: 17719305
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The pharmacoeconomic benefits of cholesterol reduction.
    Gonzalez ER
    Am J Manag Care; 1998 Feb; 4(2):223-30. PubMed ID: 10178493
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Reaching goal in hypercholesterolaemia: dual inhibition of cholesterol synthesis and absorption with simvastatin plus ezetimibe.
    Daskalopoulou SS; Mikhailidis DP
    Curr Med Res Opin; 2006 Mar; 22(3):511-28. PubMed ID: 16574035
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Stanol esters as a component of maximal dietary therapy in the National Cholesterol Education Program Adult Treatment Panel III report.
    Grundy SM
    Am J Cardiol; 2005 Jul; 96(1A):47D-50D. PubMed ID: 15992516
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effectiveness of a fenofibrate 145-mg nanoparticle tablet formulation compared with the standard 160-mg tablet in patients with coronary heart disease and dyslipidemia.
    Maciejewski S; Hilleman D
    Pharmacotherapy; 2008 May; 28(5):570-5. PubMed ID: 18447655
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Trends in ATP-III-defined high blood cholesterol prevalence, awareness, treatment and control among U.S. adults.
    Hyre AD; Muntner P; Menke A; Raggi P; He J
    Ann Epidemiol; 2007 Jul; 17(7):548-55. PubMed ID: 17395483
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.